Suppr超能文献

腹腔内热化疗在非结直肠腹膜表面恶性肿瘤中的作用。

The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies.

机构信息

Division of Surgical Oncology, Department of Surgery, University of Cincinnati, 231 Albert Sabin Way (ML 0558), Cincinnati, OH, 45267-0558, USA.

Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, USA.

出版信息

J Gastrointest Surg. 2021 Jan;25(1):303-318. doi: 10.1007/s11605-020-04771-8. Epub 2020 Aug 17.

Abstract

BACKGROUND

Peritoneal carcinomatosis, from a variety of gastrointestinal and gynecological malignancies, has been historically challenging to treat and there remains a wide range of biologic aggressiveness in these patients. Malignancies commonly associated with PC include those of colorectal, appendiceal, gastric, ovarian, sarcoma, small intestinal, and primary peritoneal origin among others. Advances in our understanding of this unique disease process have led to significant interest in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) as an emerging treatment option. The goal of CRS-HIPEC is to remove all visible macroscopic disease while preserving organ function, and then treat microscopic disease through perfusion of the peritoneal cavity with heated chemotherapy.

PURPOSE

Although recent reviews have focused on the management of peritoneal carcinomatosis secondary to colorectal cancer given the publication of several recent randomized controlled trials, the purpose of the current review is to summarize the evidence on CRS-HIPEC for non-colorectal peritoneal surface malignancies, including appendiceal neoplasms, malignant peritoneal mesothelioma, gastric cancer, and ovarian cancer.

RESULTS

While retrospective studies have clarified the importance of prognostic factors such as the peritoneal carcinomatosis index, completeness of cytoreduction, histopathological characteristics, and lymph node positivity, the lack of convincing level 1 evidence for the use of CRS-HIPEC has led to it remaining a highly controversial topic.

CONCLUSION

The decision to utilize CRS-HIPEC should involve a multidisciplinary team approach and evaluation of prognostic factors to balance the short-term morbidity of the operation with maximum long-term benefits. Large, multi-institutional groups and ongoing trials hold promise for clarifying the role of CRS-HIPEC in peritoneal surface malignancies.

摘要

背景

腹膜癌病源于多种胃肠道和妇科恶性肿瘤,历史上一直难以治疗,这些患者的生物学侵袭性差异较大。常见的与 PC 相关的恶性肿瘤包括结直肠、阑尾、胃、卵巢、肉瘤、小肠和原发性腹膜来源等。对这种独特疾病过程的认识的进步,使得细胞减灭术和腹腔内热灌注化疗(CRS-HIPEC)作为一种新兴的治疗选择引起了极大的关注。CRS-HIPEC 的目标是在保留器官功能的同时清除所有可见的宏观疾病,然后通过加热化疗灌注腹腔来治疗微观疾病。

目的

尽管最近的几项随机对照试验的发表使人们对结直肠癌继发腹膜癌病的治疗进行了综述,但本综述的目的是总结关于非结直肠癌腹膜表面恶性肿瘤(包括阑尾肿瘤、恶性腹膜间皮瘤、胃癌和卵巢癌)的 CRS-HIPEC 的证据。

结果

虽然回顾性研究阐明了预后因素的重要性,如腹膜癌病指数、细胞减灭术的完整性、组织病理学特征和淋巴结阳性,但是缺乏令人信服的 CRS-HIPEC 使用的 1 级证据,导致其仍然是一个极具争议的话题。

结论

是否使用 CRS-HIPEC 的决策应涉及多学科团队的方法和对预后因素的评估,以平衡手术的短期发病率和最大的长期获益。大型的、多机构的团体和正在进行的试验有望阐明 CRS-HIPEC 在腹膜表面恶性肿瘤中的作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验